Yatharth Hospital okays ₹3,150 crore issue in 2026

What the board approved on September 17

Yatharth Hospital & Trauma Care Services Limited said its board has approved a preferential issue of equity shares and warrants to Rasmalai Limited for up to ₹3,150.00 crore. The proposal is structured as a private placement and is subject to shareholder and regulatory approvals. Rasmalai is described as a Cyprus-based entity, and the transaction has been positioned as a minority investment. The board meeting was held on September 17, 2026, the same date previously communicated to stock exchanges as the meeting to discuss growth plans and fund raising. Alongside the proposed issuance, the board also cleared an increase in authorised share capital.

Preferential issue structure and pricing

The preferential issue has two components: equity shares and warrants, both priced at ₹985.17 per unit. For the equity leg, the company approved up to 1,30,26,516 fully paid-up equity shares, aggregating ₹1,283.33 crore. For the warrant leg, the company approved up to 1,89,47,664 warrants, aggregating ₹1,866.67 crore. The company also disclosed the payment terms for the warrants: 25% (₹246.29) is payable upfront, and the balance 75% (₹738.88) is payable upon exercise. The pricing is explicitly stated as ₹985.17 for both the shares and the warrants.

Post-issue shareholding and classification

Post completion, Rasmalai Limited is expected to hold 24.87% on a fully diluted basis. The company clarified that the fully diluted calculation factors in granted employee stock options. It also stated that upon completion, the investor will be classified as a public shareholder. The disclosure frames the deal as a minority investment rather than a change of control. Any change in shareholding will depend on the completion of the issue and, in the case of warrants, subsequent exercise.

Authorised capital increased to support the issuance

The board approved an increase in authorised share capital from ₹115 crore to ₹150 crore. The company said this requires a corresponding amendment to the Memorandum of Association. That amendment, in turn, will need shareholder consent. Such changes are typically procedural but necessary to ensure the company has sufficient authorised capital headroom for the proposed issuance.

How the fundraising decision was signalled earlier

On September 14, Yatharth Hospital informed stock exchanges that it had scheduled a board meeting for September 17, 2026. The agenda was described as discussion of growth plans and consideration of proposals to support them by raising funds. The company had listed multiple possible modes of capital raising, including debt, a rights issue, preferential allotment, qualified institutions placement (QIP), or other permissible structures. It also indicated that the instruments could include equity shares, warrants, debt securities, or other securities convertible into equity shares.

Trading window restrictions around the meeting

The company also noted that the trading window for designated persons and their immediate relatives remained closed. It will remain closed until 48 hours after the conclusion of the board meeting. Such restrictions are common around price-sensitive decisions, including fundraising.

Recent financial snapshot (converted to ₹ crore)

In the same information set, the company shared consolidated financial highlights for recent quarters. Total income for Q1FY27 was stated at ₹397.007 crore, compared with ₹267.082 crore in Q1FY26 and ₹348.671 crore in Q4FY26. Revenue from operations for Q1FY27 was ₹392.654 crore, compared with ₹259.247 crore in Q1FY26 and ₹341.563 crore in Q4FY26. Profit before tax (before exceptional items) for Q1FY27 was ₹61.205 crore, compared with ₹58.688 crore in Q1FY26 and ₹51.952 crore in Q4FY26. Net profit for Q1FY27 was ₹45.423 crore, compared with ₹42.040 crore in Q1FY26 and ₹44.698 crore in Q4FY26.

Other disclosures: dividend, ESOP, and tax demand appeals

The company stated that its board declared a first interim dividend of ₹0.50 per equity share of face value ₹10 each (5%) for FY27, amounting to ₹4.81771785 crore. It also disclosed that the board approved the “Yatharth Hospital & Trauma Care Services Employees Stock Option Scheme - 2026” (ESOP 2026) covering 2,50,000 equity shares of face value ₹10 each, subject to shareholder approval. Separately, the information set included tax demand details and said the company has filed appeals and believes, based on internal assessment, that no material liability is expected. The table shared listed, among others, Yatharth Hospital with principal demand of ₹29.66 crore and interest demand of ₹11.42 crore for assessment years AY 2014-15 to AY 2024-25, and Ramraja Multispeciality with principal demand of ₹5.64 crore and interest demand of ₹2.04 crore for AY 2023-24.

Market context: what investors will watch next

The preferential issue is explicitly subject to shareholder and regulatory approvals, so the next set of updates will likely relate to those processes and the final allotment. Investors will also track the mix between immediate equity issuance and potential dilution from warrants, given that warrants convert later if exercised. The company’s disclosures also point to multiple fundraising routes discussed in the lead-up, but the board’s approval establishes the preferential issue route as the chosen structure in this instance. With an authorised capital increase also needing shareholder consent, the timeline will depend on meeting schedules and approvals. Any subsequent disclosures on allotment, receipt of funds, and warrant exercise terms will be key milestones.

Conclusion

Yatharth Hospital’s board approval for a ₹3,150.00 crore preferential issue to Rasmalai sets out clear terms on pricing, quantities, and post-issue ownership. The company has also moved to raise authorised capital from ₹115 crore to ₹150 crore to facilitate the proposal. The next steps are shareholder and regulatory approvals, followed by allotment and, potentially over time, warrant exercises under the stated payment structure.